Letter | Published:

Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A)

Nature Medicine volume 9, pages 15331537 (2003) | Download Citation



Charcot-Marie-Tooth disease (CMT) is the most common inherited neuropathy. The predominant subtype, CMT-1A, accounts for more than 50% of all cases1 and is associated with an interstitial chromosomal duplication of 17p12 (refs. 2,3). We have generated a model of CMT-1A by introducing extra copies of the responsible disease gene, Pmp22 (encoding the peripheral myelin protein of 22 kDa), into transgenic rats4. Here, we used this model to test whether progesterone, a regulator of the myelin genes Pmp22 and myelin protein zero (Mpz) in cultured Schwann cells, can modulate the progressive neuropathy caused by moderate overexpression of Pmp22. Male transgenic rats (n = 84) were randomly assigned into three treatment groups: progesterone, progesterone antagonist (onapristone) and placebo control. Daily administration of progesterone elevated the steady-state levels of Pmp22 and Mpz mRNA in the sciatic nerve, resulting in enhanced Schwann cell pathology and a more progressive clinical neuropathy. In contrast, administration of the selective progesterone receptor antagonist reduced overexpression of Pmp22 and improved the CMT phenotype, without obvious side effects, in wild-type or transgenic rats. Taken together, these data provide proof of principle that the progesterone receptor of myelin-forming Schwann cells is a promising pharmacological target for therapy of CMT-1A.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    et al. Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation. Ann. Neurol. 51, 190–201 (2002).

  2. 2.

    et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 66, 219–232 (1991).

  3. 3.

    et al. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul. Disord. 1, 93–97 (1991).

  4. 4.

    et al. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 16, 1049–1060 (1996).

  5. 5.

    , & Molecular cell biology of Charcot-Marie-Tooth disease. Neurogenetics 4, 1–15 (2002).

  6. 6.

    et al. The phenotypic manifestations of chromosome 17p11.2 duplication. Brain 120, 465–478 (1997).

  7. 7.

    et al. Clinical variability in two pairs of identical twins with the Charcot- Marie-Tooth disease type 1A duplication. Neurology 45, 2090–2093 (1995).

  8. 8.

    et al. Progesterone as a neurosteroid: synthesis and actions in rat glial cells. J. Steroid Biochem. Mol. Biol. 69, 97–107 (1999).

  9. 9.

    et al. Progesterone synthesis and myelin formation by Schwann cells. Science 268, 1500–1503 (1995).

  10. 10.

    , , & The transcriptional basis of steroid physiology. Cold Spring Harb. Symp. Quant. Biol. 63, 577–585 (1998).

  11. 11.

    et al. Progesterone stimulates the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells. J. Neurochem. 71, 1765–1768 (1998).

  12. 12.

    et al. Progesterone derivatives are able to influence peripheral myelin protein 22 and P0 gene expression: possible mechanisms of action. J. Neurosci. Res. 56, 349–357 (1999).

  13. 13.

    et al. Progesterone synthesis and myelin formation in peripheral nerves. Brain Res. Brain Res. Rev. 37, 343–359 (2001).

  14. 14.

    , , , & Antiprogestin-progesterone interactions. Cancer Treat Res. 83, 191–212 (1996).

  15. 15.

    & Expression and transcriptional activity of progesterone receptor A and progesterone receptor B in mammalian cells. Breast Cancer Res. 4, 187–190 (2002).

  16. 16.

    et al. Progesterone receptor and the mechanism of action of progesterone antagonists. J. Steroid Biochem. Mol. Biol. 53, 449–458 (1995).

  17. 17.

    , & Plasma concentration of LH, FSH, prolactin, progesterone and estradiol- 17beta throughout the 4-day estrous cycle of the rat. Endocrinology 94, 1704–1708 (1974).

  18. 18.

    et al. Regulation of tissue-specific expression of alternative peripheral myelin protein-22 (PMP22) gene transcripts by two promoters. J. Biol. Chem. 269, 25795–25808 (1994).

  19. 19.

    et al. Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. J. Neurosci. 16, 5351–5360 (1996).

  20. 20.

    et al. Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum. Mol. Genet. 5, 563–569 (1996).

  21. 21.

    , , , & Uncoupling of myelin assembly and schwann cell differentiation by transgenic overexpression of peripheral myelin protein 22. J. Neurosci. 20, 4120–4128 (2000).

  22. 22.

    et al. Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A. Hum. Mol. Genet. 10, 1007–1018 (2001).

  23. 23.

    et al. Progesterone stimulates Krox-20 gene expression in Schwann cells. Brain Res. Mol. Brain Res. 90, 75–82 (2001).

  24. 24.

    , & Exacerbation of Charcot-Marie-tooth disease in pregnancy. Neurology 32, 1311–1314 (1982).

  25. 25.

    , , & Pregnancy and delivery in Charcot-Marie-Tooth disease type 1. Neurology 43, 2011–2016 (1993).

  26. 26.

    , , , & Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur. J. Cancer 35, 214–218 (1999).

  27. 27.

    , , , , & Effects of an antiprogestin onapristone on the endometrium of bonnet monkeys: morphometric and ultrastructural studies. Biol. Reprod. 68, 1959–1967 (2003).

Download references


We thank E. Nicksch, U. Bode and C. Stünkel for technical help; M.R. Schneider (Schering) for providing us with onapristone; C. Scheidt-Nave for statistical advice; J.R. Lupski for helpful comments on the manuscript; and members of the Nave lab for discussion. This work was supported by the Max-Planck Society and by grants from the European Union (to K.A.N.). U.S. was supported by the Swiss National Science Foundation and by the National Center for Competence in Research “Neural Plasticity and Repair”. M.W.S. was supported in part by the Departments of Clinical Neurophysiology and Neurology at the University of Göttingen.

Author information

Author notes

    • Michael W Sereda
    •  & Gerd Meyer zu Hörste

    These authors contributed equally to this work.


  1. Max-Planck Institute of Experimental Medicine, Department of Neurogenetics, Hermann-Rein-Str. 3, D-37075 Göttingen, Germany.

    • Michael W Sereda
    • , Gerd Meyer zu Hörste
    • , Naureen Uzma
    •  & Klaus-Armin Nave
  2. Departments of Neurology and Clinical Neurophysiology, University of Göttingen, Robert-Koch Str. 40, D-37075 Göttingen, Germany.

    • Michael W Sereda
  3. Institute of Cell Biology, Department of Biology, Swiss Federal Institute of Technology, ETH Hoenggerberg, 8093 Zürich, Switzerland.

    • Ueli Suter


  1. Search for Michael W Sereda in:

  2. Search for Gerd Meyer zu Hörste in:

  3. Search for Ueli Suter in:

  4. Search for Naureen Uzma in:

  5. Search for Klaus-Armin Nave in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Klaus-Armin Nave.

Supplementary information

About this article

Publication history






Further reading